ROHSTOFF INTERNATIONAL

14:00 | 10.11.2017
ERS Genomics and Cellecta, Inc. Sign License Agreement on CRISPR/Cas9 Genome Editing Patents for Tools and Services

ERS Genomics Ltd. and Cellecta, Inc. announced today a non-exclusive
license agreement to provide Cellecta with worldwide access to ERS
Genomics’ CRISPR/Cas9 genome editing intellectual property for use in
informing research tools and services. ERS Genomics holds rights to the
foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle
Charpentier, who along with Dr. Jennifer Doudna at the University of
California, Berkeley, adapted the CRISPR system into a breakthrough gene
editing technology.

Cellecta is the first commercial provider of a lentiviral-based CRISPR
library targeting all 19,000+ human protein-coding genes, and an
industry leader in RNAi and CRISPR technologies for the discovery and
characterization of novel therapeutic targets. Its off-the-shelf and
custom genetic libraries, constructs, and kits are widely used in
commercial and academic laboratories researching disease progression and
therapeutic interventions.

“As a leader in advancing high-throughput genetic screening and
discovery applications for novel therapeutic targets and drugs, Cellecta
is adding to the growing list of companies who are making the
CRISPR/Cas9 technology broadly accessible to the scientific community,”
said Eric Rhodes, CEO of ERS Genomics. “We are thrilled to be partnering
with Cellecta on these aligned interests.”

“CRISPR/Cas9 technology is proving to be an increasingly valuable tool
for target discovery and validation applications,” said Dr. Paul Diehl,
COO of Cellecta. “Cellecta is pleased to offer a growing portfolio of
products and services to aid researchers in obtaining a deeper
understanding of gene function using this important technology.”

Dr. Emmanuelle Charpentier’s research unveiled the key components and
mechanisms of the CRISPR/Cas9 system that led to the landmark
publication with Jennifer Doudna (Jinek,
Chylinski et al., 2012), which laid the foundation for the use of
CRISPR/Cas9 as a highly versatile and precise genome editing tool.

Financial details of the agreement were not disclosed.
About ERS Genomics
ERS Genomics was formed to provide broad access to the
foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle
Charpentier. Non-exclusive licenses are available for research and sale
of products and services across multiple fields including: research
tools, kits, reagents; discovery of novel targets for therapeutic
intervention; cell lines for discovery and screening of novel drug
candidates; GMP production of healthcare products; production of
industrial materials such as enzymes, biofuels and chemicals; and
synthetic biology. For additional information please visit www.ersgenomics.com.
About Cellecta:
Cellecta, Inc. is the first commercial provider of a lentiviral-based
CRISPR library targeting all 19,000+ human protein-coding genes.
Cellecta is an industry leader in RNAi and CRISPR technologies for the
discovery and characterization of novel therapeutic targets, and
targeted gene profiling for biomarker discovery. Numerous scientific
papers have been published citing Cellecta’s functional genomics
portfolio offering gene knockout and knockdown screens, custom and
genome-wide RNAi and CRISPR libraries, cell engineering, RNAi and CRISPR
construct services, and targeted expression profiling and biomarker
discovery in disease samples. Cellecta, Inc. is headquartered in
Mountain View, California. Further information about the company and its
functional genomic products and services may be found online at www.cellecta.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20171110005208/en/


NEWSLETTER

Abonnieren Sie jetzt unseren
aktuellen Newsletter

WIRTSCHAFTSNACHRICHTEN

22:17 Uhr | 22.11.2017
Aktien New York Schluss: Dow im ...


21:35 Uhr | 22.11.2017
dpa-AFX Überblick: Ausgewählte ...


21:11 Uhr | 22.11.2017
Devisen: Eurokurs steigt über ...


20:37 Uhr | 22.11.2017
OTS: Börsen-Zeitung / ...


20:32 Uhr | 22.11.2017
ANALYSE-FLASH: SocGen hebt Munich ...